Medexus Pharmaceuticals Stock Key Fundamental Indicators
| MDP Stock | 2.81 0.03 1.06% |
As of the 12th of February 2026, Medexus Pharmaceuticals secures the Risk Adjusted Performance of 0.0407, downside deviation of 2.08, and Mean Deviation of 1.61. In connection with fundamental indicators, the technical analysis model lets you check existing technical drivers of Medexus Pharmaceuticals, as well as the relationship between them.
Medexus Pharmaceuticals Total Revenue |
|
Gross Profit | Profit Margin | Market Capitalization | Enterprise Value Revenue 0.7643 | Revenue |
Medexus | Select Account or Indicator |
Medexus Pharmaceuticals Balance Sheet | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Medexus Pharmaceuticals Income Statement | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Medexus Pharmaceuticals Cash Flow Statement | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Ratios | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Medexus Pharmaceuticals Valuation Data | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Medexus Fundamental Market Drivers
| Forward Price Earnings | 4.7304 | |
| Cash And Short Term Investments | 24 M |
Medexus Return On Asset Driver Correlations
Understanding the fundamental principles of building solid financial models for Medexus Pharmaceuticals is extremely important. It helps to project a fair market value of Medexus Stock properly, considering its historical fundamentals such as Return On Asset. Since Medexus Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Medexus Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Medexus Pharmaceuticals' interrelated accounts and indicators.
Click cells to compare fundamentals
Medexus Pharmaceuticals 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Medexus Pharmaceuticals' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Medexus Pharmaceuticals.
| 11/14/2025 |
| 02/12/2026 |
If you would invest 0.00 in Medexus Pharmaceuticals on November 14, 2025 and sell it all today you would earn a total of 0.00 from holding Medexus Pharmaceuticals or generate 0.0% return on investment in Medexus Pharmaceuticals over 90 days. Medexus Pharmaceuticals is related to or competes with Cardiol Therapeutics. Medexus Pharmaceuticals is entity of Canada More
Medexus Pharmaceuticals Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Medexus Pharmaceuticals' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Medexus Pharmaceuticals upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 2.08 | |||
| Information Ratio | (0) | |||
| Maximum Drawdown | 11.22 | |||
| Value At Risk | (3.60) | |||
| Potential Upside | 3.81 |
Medexus Pharmaceuticals Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Medexus Pharmaceuticals' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Medexus Pharmaceuticals' standard deviation. In reality, there are many statistical measures that can use Medexus Pharmaceuticals historical prices to predict the future Medexus Pharmaceuticals' volatility.| Risk Adjusted Performance | 0.0407 | |||
| Jensen Alpha | 0.0784 | |||
| Total Risk Alpha | (0.17) | |||
| Sortino Ratio | (0) | |||
| Treynor Ratio | 1.12 |
Medexus Pharmaceuticals February 12, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.0407 | |||
| Market Risk Adjusted Performance | 1.13 | |||
| Mean Deviation | 1.61 | |||
| Semi Deviation | 1.87 | |||
| Downside Deviation | 2.08 | |||
| Coefficient Of Variation | 2307.89 | |||
| Standard Deviation | 2.2 | |||
| Variance | 4.86 | |||
| Information Ratio | (0) | |||
| Jensen Alpha | 0.0784 | |||
| Total Risk Alpha | (0.17) | |||
| Sortino Ratio | (0) | |||
| Treynor Ratio | 1.12 | |||
| Maximum Drawdown | 11.22 | |||
| Value At Risk | (3.60) | |||
| Potential Upside | 3.81 | |||
| Downside Variance | 4.32 | |||
| Semi Variance | 3.48 | |||
| Expected Short fall | (1.86) | |||
| Skewness | 0.6093 | |||
| Kurtosis | 1.48 |
Medexus Pharmaceuticals Backtested Returns
As of now, Medexus Stock is relatively risky. Medexus Pharmaceuticals has Sharpe Ratio of 0.0398, which conveys that the firm had a 0.0398 % return per unit of risk over the last 3 months. We have found twenty-seven technical indicators for Medexus Pharmaceuticals, which you can use to evaluate the volatility of the firm. Please verify Medexus Pharmaceuticals' Mean Deviation of 1.61, risk adjusted performance of 0.0407, and Downside Deviation of 2.08 to check out if the risk estimate we provide is consistent with the expected return of 0.0911%. Medexus Pharmaceuticals has a performance score of 3 on a scale of 0 to 100. The company secures a Beta (Market Risk) of 0.0762, which conveys not very significant fluctuations relative to the market. As returns on the market increase, Medexus Pharmaceuticals' returns are expected to increase less than the market. However, during the bear market, the loss of holding Medexus Pharmaceuticals is expected to be smaller as well. Medexus Pharmaceuticals right now secures a risk of 2.29%. Please verify Medexus Pharmaceuticals information ratio, downside variance, day median price, as well as the relationship between the treynor ratio and kurtosis , to decide if Medexus Pharmaceuticals will be following its current price movements.
Auto-correlation | -0.11 |
Insignificant reverse predictability
Medexus Pharmaceuticals has insignificant reverse predictability. Overlapping area represents the amount of predictability between Medexus Pharmaceuticals time series from 14th of November 2025 to 29th of December 2025 and 29th of December 2025 to 12th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Medexus Pharmaceuticals price movement. The serial correlation of -0.11 indicates that less than 11.0% of current Medexus Pharmaceuticals price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.11 | |
| Spearman Rank Test | -0.11 | |
| Residual Average | 0.0 | |
| Price Variance | 0.0 |
Return on Asset measures overall efficiency of a company in generating profits from its total assets. It is expressed as the percentage of profits earned per dollar of Asset. A low ROA typically means that a company is asset-intensive and therefore will needs more money to continue generating revenue in the future.
| Competition |
Medexus Total Assets
Total Assets |
|
Based on the latest financial disclosure, Medexus Pharmaceuticals has a Return On Asset of 0.0254. This is 100.29% lower than that of the Pharmaceuticals sector and significantly higher than that of the Health Care industry. The return on asset for all Canada stocks is 118.14% lower than that of the firm.
Medexus Pharmaceuticals Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Medexus Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Medexus Pharmaceuticals value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Medexus Pharmaceuticals competition to find correlations between indicators driving Medexus Pharmaceuticals's intrinsic value. More Info.Medexus Pharmaceuticals is regarded second in return on equity category among its peers. It is considered to be number one stock in return on asset category among its peers reporting about 2.82 of Return On Asset per Return On Equity. At this time, Medexus Pharmaceuticals' Return On Equity is very stable compared to the past year. Comparative valuation analysis is a catch-all model that can be used if you cannot value Medexus Pharmaceuticals by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Medexus Pharmaceuticals' Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.Medexus Return On Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Medexus Pharmaceuticals' direct or indirect competition against its Return On Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Medexus Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Medexus Pharmaceuticals by comparing valuation metrics of similar companies.Medexus Pharmaceuticals is currently under evaluation in return on asset category among its peers.
Medexus Pharmaceuticals Current Valuation Drivers
We derive many important indicators used in calculating different scores of Medexus Pharmaceuticals from analyzing Medexus Pharmaceuticals' financial statements. These drivers represent accounts that assess Medexus Pharmaceuticals' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Medexus Pharmaceuticals' important valuation drivers and their relationship over time.
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 (projected) | ||
| Market Cap | 61.1M | 32.0M | 35.9M | 62.5M | 71.9M | 102.7M | |
| Enterprise Value | 103.4M | 109.0M | 80.6M | 75.7M | 87.0M | 127.0M |
Medexus Fundamentals
| Return On Equity | 0.009 | ||||
| Return On Asset | 0.0254 | ||||
| Profit Margin | 0 % | ||||
| Operating Margin | 0.07 % | ||||
| Current Valuation | 107.92 M | ||||
| Shares Outstanding | 32.42 M | ||||
| Shares Owned By Insiders | 7.21 % | ||||
| Shares Owned By Institutions | 3.35 % | ||||
| Number Of Shares Shorted | 102.71 K | ||||
| Price To Book | 1.29 X | ||||
| Price To Sales | 0.88 X | ||||
| Revenue | 108.33 M | ||||
| Gross Profit | 63.95 M | ||||
| EBITDA | 16.81 M | ||||
| Net Income | 2.25 M | ||||
| Cash And Equivalents | 23.97 M | ||||
| Total Debt | 37.18 M | ||||
| Book Value Per Share | 2.19 X | ||||
| Cash Flow From Operations | 24.03 M | ||||
| Short Ratio | 2.48 X | ||||
| Earnings Per Share | 0.01 X | ||||
| Target Price | 6.89 | ||||
| Number Of Employees | 91 | ||||
| Beta | 1.98 | ||||
| Market Capitalization | 92.07 M | ||||
| Total Asset | 171.84 M | ||||
| Retained Earnings | (61.99 M) | ||||
| Working Capital | (16.74 M) | ||||
| Net Asset | 171.84 M |
About Medexus Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Medexus Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Medexus Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Medexus Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.| Last Reported | Projected for Next Year | ||
| Current Deferred Revenue | 46 M | 48.3 M | |
| Total Revenue | 124.6 M | 130.8 M | |
| Cost Of Revenue | 59.5 M | 62.5 M | |
| Sales General And Administrative To Revenue | 0.30 | 0.40 | |
| Research And Ddevelopement To Revenue | 0.09 | 0.14 | |
| Capex To Revenue | 0.03 | 0.03 | |
| Revenue Per Share | 3.78 | 2.34 | |
| Ebit Per Revenue | 0.07 | 0.07 |
Pair Trading with Medexus Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Medexus Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Medexus Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Moving together with Medexus Stock
Moving against Medexus Stock
The ability to find closely correlated positions to Medexus Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Medexus Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Medexus Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Medexus Pharmaceuticals to buy it.
The correlation of Medexus Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Medexus Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Medexus Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Medexus Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Other Information on Investing in Medexus Stock
Medexus Pharmaceuticals financial ratios help investors to determine whether Medexus Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Medexus with respect to the benefits of owning Medexus Pharmaceuticals security.